A multicentre randomized double-blind placebo-controlled phase III study of the efficacy and safety of xeligekimab (GR1501) in patients with moderate-to-severe plaque psoriasis
1. 系统已在2025-12-31 10:15:34对应助文件进行删除
2. 如有需要请重新发布求助信息
注: 所有应助的资源仅供学习交流使用, 不得违反相关法律法规
DOI: 10.1093/bjd/ljae062
文献链接: https://academic.oup.com/bjd/article/191/3/336/7608989
其他信息:
出版社: Oxford University Press (OUP)
作者: Lin Cai; Congjun Jiang; Guoqiang Zhang; Hong Fang; Jinyan Wang; Yumei Li; Hui Xu; Rong Xiao; Yangfeng Ding; Kun Huang; Chunlei Zhang; Litao Zhang; Bin Chen; Xinsuo Duan; Weili Pan; Guangming Han; Rongyi Chen; Lunfei Liu; Shoumin Zhang; Juan Tao; Xiaowen Pang; Jianbin Yu; Huiping Wang; Yi Zhao; Chengxin Li; Xiaojing Kang; Lanying Qin; Xiaofang Zhu; Juan Su; Shanshan Li; Chunjun Yang; Wenli Feng; Tiechi Lei; Shan Jiang; Ruihua Fang; Mao Lin; Qianjin Lu; Chunxing Xu; Wei Wang; Jianzhong Zhang
全文下载地址: https://academic.oup.com/bjd/advance-article-pdf/doi/10.1093/bjd/ljae062/58346402/ljae062.pdf
